2023 was a tough 12 months for the biopharma business, with many providers downsizing and restructuring their workforces to remain afloat. You'll find signs of recovery, as mergers and acquisitions picked up over the pharmaceutical and lifetime sciences field in the latter A part of 2023 and have continued their https://sites.google.com/view/bio-sites/blog